Skip to Content

Insider Selling: A Major Shareholder of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Sells 110,000 Shares of Stock

Insider Selling: A Major Shareholder of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Sells 110,000 Shares of Stock

Ecor1 Capital, L.L.C., a significant shareholder in the company, recently completed a transaction in which it sold 110,000 Voyager Therapeutics, Inc. (NASDAQ: VYGR) stock. This transaction took place on January 11. There was a sale of shares with a total value of $935,000.00, accomplished at an average price of $8.50 per share. Following the completion of the transaction, the insider will continue to hold a total of 3,851,507 shares of the company, which will result in a current market value of approximately $32,737,809.50. Should you follow this link, you will be taken to the S.E.C. filing in which the transaction was discussed in greater detail. Any transactions in which large shareholders control more than 10% of a company’s equity must be reported to the Securities and Exchange Commission (S.E.C.) by the law.

In addition, Ecor1 Capital, L.L.C. was in charge of the recent closing of the transaction(s) that are listed below:

NASDAQ After a gain of $1.00 throughout Wednesday’s trading hours, the price of VYGR climbed up to $8.95. The total number of shares transacted by the company was 1,071,222, which is higher than the typical volume of 1,007,172 shares. The company’s moving average over the previous 200 days is $6.07, while the moving average over the previous 50 days is $5.78. In the past 52 weeks, the price of a share of Voyager Therapeutics, Inc. has ranged from $2.60 to $10.60, reaching a low of $2.60 and a high of $10.60. The current price-to-earnings ratio for the company is -18.74, and its beta value is 0.93. The market value of the company is $345.53 million at the moment.

Separately, in a research note published on Monday, November 14, shifted the rating they had previously assigned to shares of Voyager Therapeutics from a “hold” rating to a “buy” rating. Previously, they had given the shares of Voyager Therapeutics a “hold” rating.

Important shareholders have just recently made adjustments to their existing stock holdings. PDT Partners L.L.C. made a new investment of approximately $60,000 in Voyager Therapeutics during the second quarter of 2018 to acquire a new investment in the company. During the third quarter, the Royal Bank of Canada achieved a 1,746.6% increase in the proportion of Voyager Therapeutics stock it owned. Royal Bank of Canada now holds 12,004 shares of the company’s stock, which has a value of $71,000 after purchasing an additional 11,354 shares during the period. During the period in question, these shares were purchased. Landscape Capital Management, L.L.C. invested in Voyager Therapeutics for $96,000 during the second quarter of 2018. This investment was made in 2018. During the second quarter of the fiscal year, Franklin Resources Inc. invested in Voyager Therapeutics for a total of 104 thousand dollars. And lastly, during the second quarter, Assenagon Asset Management S.A. invested 117 thousand dollars in Voyager Therapeutics, establishing a new position in the company. Institutional investors and hedge funds collectively own 59.58% of the total number of shares in the company, making up the majority of the shareholders.

Voyager Treatments, Inc., a company that focuses on gene therapy, is committed to the research and development of novel therapeutics as well as innovative platform technologies. This mission drives the company’s day-to-day operations. The company’s lead clinical candidate, VY-AADC, is currently participating in a Phase 1 clinical trial conducted with an open label to investigate its efficacy as a treatment for Parkinson’s disease. It has preclinical programs referred to as VY-SOD102 for amyotrophic lateral sclerosis, VY-HTT01 for Huntington’s disease, VY-FXN01 for Friedreich’s ataxia, and the Tau program for the treatment of tauopathies such as Alzheimer’s disease, progressive supranuclear palsy, frontotemporal dementia, and spinal muscular atrophy. These therapies are currently under development as potential treatments for tauopathies.


Leave a comment

Your email address will not be published. Required fields are marked *